30
Participants
Start Date
January 22, 2020
Primary Completion Date
June 14, 2024
Study Completion Date
October 31, 2025
Ramucirumab
Administered IV
Cyclophosphamide
Administered orally
Vinorelbine
Administered IV
Ospedale Pediatrico Bambino Gesù, Rome
Royal Children's Hospital, Parkville
Memorial Sloan Kettering Cancer Center, New York
Children's Hospital of Philadelphia (CHOP), Philadelphia
Children's National Medical Center, Washington D.C.
Humanitas, Rozzano
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Universitaetsklinikum Hamburg-Eppendorf, Hamburg
Azienda Ospedaliera di Padova, Padua
Hospital Universitario Virgen Del Rocio, Seville
Universitaetsklinikum Essen, Essen
Washington University, St Louis
Universitaetsklinikum Freiburg, Freiburg im Breisgau
Phoenix Children's Hospital, Phoenix
Children's Hospital of Los Angeles, Los Angeles
National Cancer Center Hospital, Chuo-ku
Kyushu University Hospital, Fukuoka
Hospital Universitari Vall d'Hebron, Barcelona
University College London Hospital, London
Royal Marsden Hospital (Sutton), London
Royal Manchester Children's Hospital, Manchester
The Christie, Manchester
Eli Lilly and Company
INDUSTRY